Genenta Science S.p.A.
GNTANasdaq
$1.55
↑ +7.6%Jul 17 close · end-of-day
Price
1Y↓ -59.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$30.6M
Enterprise Value
$30.6M
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
—
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
—
ROIC
—
Debt / Equity
—
Net Cash
—
Return 1Y
-59.0%
Company profile
Genenta Science S.p.A. engages in the development of hematopoietic stem cell gene therapies. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
- CEO
- Pierluigi Paracchi
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 7
- Website
- genenta.com
Earnings
No reported earnings periods on file.
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | — | — | — | — | — |
| Net income | — | — | — | — | — |
| Diluted EPS | — | — | — | — | — |
| Operating cash flow | — | — | — | — | — |
| Free cash flow | — | — | — | — | — |
| Gross margin | — | — | — | — | — |
| Operating margin | — | — | — | — | — |
| Net margin | — | — | — | — | — |
No quarterly data.
Company news
Jul 17, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.